Drugs / MCARH109
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05431608 | Jun 2022 → Jun 2027 expected | plasma cell myeloma, refractory plasma cell neoplasm | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04555551 | Sep 2020 → Aug 2027 expected | plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MCARH109 | “MCARH109 and MCARH125 will be administered 2-7 days following the completion of conditioning chemotherapy.” NCT05431608 ↗ |
| Modality | Cell therapy | “MCARH109 is a first-in-class G protein-coupled receptor, class C, group 5, member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy” PMID 39631041 ↗ Dec 2024 |
| Target | GPRC5D | “GPRC5D-targeted CAR T cells” PMID 36170501 ↗ Sep 2022 |